Particle.news
Download on the App Store

Wireless Retinal Implant Restores Central Vision in Advanced AMD, NEJM Study Finds

Peer-reviewed results from the PRIMAvera trial show clinically meaningful central-reading gains in most participants with geographic atrophy.

Overview

  • Of 32 patients completing 12 months, 27 (84%) used the system to read letters, numbers or words, with an average improvement of about 25 letters and a maximum gain of 59 letters.
  • The PRIMA system pairs a 2×2 mm subretinal photovoltaic chip with augmented‑reality glasses that project infrared images to stimulate remaining retinal cells without external wires.
  • Nineteen of 32 participants experienced transient ocular adverse events that resolved within two months, and investigators reported no loss of residual peripheral vision in the treated eye.
  • Implants are activated about four to five weeks after surgery and require months of visual rehabilitation, with the vitreoretinal procedure typically completed in under two hours by trained surgeons.
  • Following publication, manufacturer Science Corporation applied for clinical authorization in Europe and the United States, as teams work on grayscale software, higher‑resolution chips and improved eyewear for wider use.